Morris Silver, MD
Gastroenterology · Beverly Hills, CANPI 1871546127
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,670 of the $40,264 with a category attached, or 73.7%. Phathom Pharmaceuticals, Inc. accounts for 75.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $25,175 and has fallen 60.1% since, to $10,047 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $83.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$31K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- AbbVie$2K
- Vertex$783
- Redhill Biopharma Inc.$536
- Sanofi$525
- plus $3K from 16 others
Across 23 payments — averaging $6370.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$116K
- Amgen$31K
Across 5 payments — averaging $11,040 each. An ownership or investment interest held by the physician or an immediate family member.
- Adcura, Inc.$55K
What the payments were for
- Consulting fees$7832%
- Speaking & faculty fees$29,67074%
- Travel & lodging$1000%
- Food & beverage$9,57824%
- Education$800%
- Gifts$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 47 | $30,518 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 212 | $3,617 |
| AbbVie | 68 | $1,595 |
| Vertex | 2 | $783 |
| Redhill Biopharma Inc. | 24 | $536 |
| Sanofi | 17 | $525 |
| QOL Medical, LLC | 18 | $505 |
| Ardelyx, Inc. | 22 | $478 |
| Johnson & Johnson | 18 | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $363 |
| Regeneron Healthcare Solutions, Inc. | 7 | $225 |
| Lilly USA, LLC | 6 | $173 |
| Ferring Pharmaceuticals Inc. | 5 | $85 |
| Madrigal Pharmaceuticals | 2 | $82 |
| Ironwood Pharmaceuticals, Inc | 3 | $81 |
| Gilead | 4 | $65 |
| Nestle Healthcare Nutrition Inc. | 3 | $64 |
| Braintree Laboratories, Inc. | 1 | $53 |
| Novo Nordisk | 1 | $30 |
| Boehringer Ingelheim | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,265 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 19 | $26,423 |
| VoqueznaVonoprazan Fumarate | 16 | $9,521 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 36 | $4,876 |
| Pantoprazole Sodium | 80 | $523 |
| Omeprazole | 22 | $144 |
| Famotidine | 25 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Phathom Pharmaceuticals, Inc.Voquezna | $30,518 | $9,52116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $3,617 | $4,87636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Beverly Hills
- Shahab MehdizadehBeverly Hills$163K
- Seper DezfoliBeverly Hills$146K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.